SCHEMBL2851345

SCHEMBL2851345

COc1ccc(-c2nnc3c4ccccc4c(Nc4cccc(NC(=O)c5cccc(OC)c5)c4)nn23)cc1

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.55
POLB P06746 2/20 0.55
KCNK9 Q9NPC2 3/20 0.53
KCNK3 O14649 3/20 0.53
SMN1; SMN2 Q16637 3/20 0.51
NPC1 O15118 3/20 0.51
RAB9A P51151 3/20 0.51
LMNA P02545 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50
TSHR P16473 2/20 0.49
ELANE P08246 1/20 0.49
ALOX15 P16050 1/20 0.49
HSD17B10 Q99714 1/20 0.49
TP53 P04637 2/20 0.49
ALDH1A1 P00352 1/20 0.47
RXFP1 Q9HBX9 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2831680 0.96 MAPT (0.55) MAPTPOLBKCNK9KCNK3SMN1; SMN2
SCHEMBL2827889 0.95 MAPT (0.61) MAPTPOLBKCNK9KCNK3SMN1; SMN2
SCHEMBL2829812 0.94 MAPT (0.52) MAPTPOLBSMN1; SMN2NPC1RAB9A
SCHEMBL2828630 0.94 MAPT (0.57) MAPTPOLBKCNK9KCNK3SMN1; SMN2
SCHEMBL2832052 0.93 MAPT (0.56) MAPTPOLBKCNK9SMN1; SMN2NPC1
SCHEMBL2825452 0.93 MAPT (0.54) MAPTPOLBSMN1; SMN2NPC1RAB9A
SCHEMBL2825351 0.91 MAPT (0.56) MAPTPOLBKCNK9SMN1; SMN2NPC1
SCHEMBL2823650 0.90 MAPT (0.54) MAPTPOLBKCNK9KCNK3SMN1; SMN2
SCHEMBL2823796 0.90 SMN1; SMN2 (0.53) MAPTPOLBKCNK9KCNK3SMN1; SMN2
SCHEMBL2825894 0.90 MAPT (0.51) MAPTPOLBSMN1; SMN2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851472-B2 Triazolophthalazines NYCOMED GMBH (DE) 2010-12-14 US disclosed
US-20100286140-A1 TRIAZOLOPHTHALAZINES NYCOMED GMBH (DE) 2010-11-11 US disclosed
EP-1791543-B1 TRIAZOLOPHTHALAZINES NYCOMED GMBH (DE) 2010-06-16 EP disclosed
US-20090005372-A1 Triazolophthalazines ALTANA PHARMA AG (DE) 2009-01-01 US disclosed
EP-1791543-A2 TRIAZOLOPHTHALAZINES Altana Pharma AG (DE) 2007-06-06 EP disclosed
WO-2006024640-A2 TRIAZOLOPHTHALAZINES ALTANA PHARMA AG (DE) 2006-03-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100286140-A1 TRIAZOLOPHTHALAZINES PDE2A, PDE12, PDE3A MAPT 3816/4885POLB 2057/4885KCNK9 2520/4885
US-20090005372-A1 Triazolophthalazines PDE2A, PDE12, PDE3A MAPT 3816/4885POLB 2057/4885KCNK9 2520/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.